Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia

详细信息    查看全文

• 作者：Ying Wang ; Dong Lin ; Hui Wei ; Wei Li ; Bingcheng Liu…
• 关键词：Acute promyelocytic leukemia ; Homoharringtonine ; Overall survival ; Body mass index ; Follow ; up
• 刊名：International Journal of Hematology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：101
• 期：3
• 页码：279-285
• 全文大小：474 KB
• 参考文献：1. Bian, S, Wang, Z, Hao, Y, Yan, W, Yang, T, Qian, L (1988) Combination chemotherapy for acute nonlymphoblastic leukemia in adult: a comparison of HAT and D(A)AT protocols. Chin J Hematol 9: pp. 449-452
  2. Thé, H, Lavau, C, Marchio, A, Chomienne, C, Degos, L, Dejean, A (1991) The PML-RAR alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: pp. 675-684 CrossRef
  3. Wang, ZY, Chen, Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: pp. 2505-2515 CrossRef
  4. Sanz, MA, Grimwade, D, Tallman, MS, Lowenberg, B, Fenaux, P, Estey, EH (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 113: pp. 1875-1891 CrossRef
  5. Frankel, SR, Eardley, A, Lauwers, G, Weiss, M, Warrell, RP (1992) The “retinoic acid syndrome-in acute promyelocytic leukemia. Ann Inter Med 117: pp. 292-296 CrossRef
  6. Cheson BD, Bennett JM, Kopecky KJ, Büchner, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-.
  7. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-3.
  8. Haslam, DW, James, WPT (2005) Obesity. Lancet 366: pp. 1197-1209 CrossRef
  9. Mi, Y, Xue, Y, Yu, W, Liu, S, Zhao, Y, Meng, Q (2008) Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma 49: pp. 524-530 CrossRef
  10. Liu, J, Mi, Y, Fu, M, Yu, W, Wang, Y, Lin, D (2009) Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Am J Hematol 84: pp. 422-427 CrossRef
  11. Jin, J, Wang, JX, Chen, FF, Wu, DP, Hu, J, Zhou, JF (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomized, controlled phase 3 trial. Lancet Oncol 14: pp. 599-608 CrossRef
  12. Sanz, MA, Martín, G, González, M, León, A, Rayón, C, Rivas, C (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood 103: pp. 1237-1243 CrossRef
  13. Adés, L, Chevret, S, Raffoux, E, Botton, S, Guerci, A, Pigneux, A (2006) Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24: pp. 5703-5710 CrossRef
  14. Tallman, MS, Nabhan, C, Feusner, JH, Rowe, JM (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99: pp. 759-767 CrossRef
  15. Estey, E, Thall, P, Kantarjian, H, Pierce, S, Kornblau, S, Keating, M (1997) Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11: pp. 1661-1664 CrossRef
  16. Thomas, X, Fiere, D, Archimbaud, E (1998) Influence of increased body mass index on drug toxicity in patients with acute promyelocytic
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘

We conducted a retrospective study to evaluate the efficacy of combining homoharringtonine (HHT) with all-trans-retinoic acid (ATRA)-based induction therapy, followed by three courses of consolidation chemotherapy and 2-year sequential maintenance therapy in acute promyelocytic leukemia (APL). Fifty-three patients were enrolled in the study. The complete remission (CR) rate was 100?%. No patient died during induction therapy. The 9-year event-free survival (EFS) and 9-year overall survival (OS) for all patients were 79.0 and 83.0?%, respectively. Outcome estimates according to the body mass index (BMI) were carried out. Twenty-three (43.4?%) were underweight/normal (BMI?2), whereas 30 patients (56.6?%) were overweight/obese (BMI?≥?3.0?kg/m2). Underweight/normal-weight patients had a 9-year OS of 100?%, compared with 73.0?% for overweight/obese patients (P?=?0.044). These results indicate that HHT plus ATRA-based induction and consolidation therapy may be a highly efficacious treatment option for newly diagnosed APL. Increased BMI had an adverse prognostic impact in APL.